Ribon Therapeutics has emerged out of stealth after three years of developing a lead asset targeting cancer based on research at MIT, UT Southwestern and Harvard Medical School.

The world is less than a week into 2019 and already universities are proving they have every intention of building and expanding on the historic successes of the past 12 months – stay tuned for the annual data review in this month’s magazine.
There is Friday’s acquisition of CoreBiome, a US-based genomic and informatics technology spinout of University of Michigan by point-of-care diagnostics devices manufacturer OraSure Technologies, less than 18 months after the spinout’s formation.
There is Cabaletta Bio,…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).